Using GLP-1 Receptor Agonist to Reduce Heart Injury After Non-cardiac Surgery
Glucagon-like Peptide-1 Receptor Agonist for Reduction of Myocardial Injury After Non-Cardiac Surgery
This study is testing if a single dose of a diabetes medication can help reduce heart injury in patients having non-heart-related surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 372 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 3 sites (Hong Kong, Hong Kong SAR and 2 other locations) |
| Trial ID | NCT06324461 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of a single subcutaneous dose of Dulaglutide, a GLP-1 receptor agonist, in reducing myocardial injury in patients undergoing elective non-cardiac surgery. A total of 372 patients will be randomly assigned to receive either the medication or routine care, with assessments including cardiac evaluations and troponin level measurements to determine the drug's efficacy. The study aims to address the significant risk of myocardial injury, which is a leading cause of complications and mortality in the post-operative period. By evaluating the safety and effectiveness of this prophylactic approach, the trial seeks to provide new insights into managing peri-operative cardiovascular risks.
Who should consider this trial
Good fit: Ideal candidates are adults aged 45 and older scheduled for elective intermediate to high-risk non-cardiac surgery requiring general anesthesia.
Not a fit: Patients with recent history of severe cardiovascular issues, pancreatitis, or certain endocrine disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of myocardial injury in patients undergoing non-cardiac surgeries, improving post-operative outcomes.
How similar studies have performed: While there have been studies exploring GLP-1 receptor agonists in various contexts, this specific application for reducing myocardial injury post-surgery is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Planned elective intermediate to high risk non-cardiac surgery * Anticipated to remain hospitalized for at least one night after surgery * Voluntarily agrees to participate by providing written informed consent Exclusion Criteria: * History of symptomatic hypoglycemia within 1 month of recruitment * History of pancreatitis * Diabetic retinopathy * Personal or family history of medullary thyroid carcinoma (MTC) * Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment * Stroke or transient ischemic attack within 1 month of recruitment * Known severe liver disease (Child-Pugh B or C) * Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min) * Recent use of GLP-1 RA within 1 month of recruitment * Known allergy or hypersensitivity to GLP-1 RA * Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding * Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
Where this trial is running
Hong Kong, Hong Kong SAR and 2 other locations
- Duchess of Kent Children's Hospital at Sandy Bay — Hong Kong, Hong Kong SAR, China (Not_yet_recruiting)
- Queen Mary Hospital — Hong Kong, Hong Kong SAR, China (Recruiting)
- Tung Wah Hospital — Hong Kong, Hong Kong SAR, China (Recruiting)
Study contacts
- Principal investigator: Chun Ka Wong, Clinical Assistant Professor — The University of Hong Kong
- Study coordinator: Chun Ka Wong, Clinical Assistant Professor
- Email: wongeck@hku.hk
- Phone: +852 2255 3597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.